AI assistant
IDEXX LABORATORIES INC /DE — Director's Dealing 2018
May 21, 2018
30016_dirs_2018-05-21_04ea71ab-49f2-4aba-a8b8-628b5489f16c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2018-05-09
Reporting Person: Turner Kathy V (Corporate Vice President)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 2806 | Direct |
| Common Stock | 100 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Restricted Stock Unit | $ | Common Stock (3870) | Direct | ||
| Non-Qualified Stock Option (right-to-buy) | $64.24 | 2024-05-31 | Common Stock (276) | Direct | |
| Incentive Stock Option (right-to-buy) | $64.24 | 2024-05-31 | Common Stock (7780) | Direct | |
| Non-Qualified Stock Option (right-to-buy) | $79.54 | 2025-02-13 | Common Stock (19354) | Direct | |
| Incentive Stock Option (right-to-buy) | $79.54 | 2025-02-13 | Common Stock (1256) | Direct | |
| Non-Qualified Stock Option (right-to-buy) | $67.85 | 2026-02-13 | Common Stock (22028) | Direct | |
| Incentive Stock Option (right-to-buy) | $67.85 | 2026-02-13 | Common Stock (1476) | Direct | |
| Non-Qualified Stock Option (right-to-buy) | $141.60 | 2027-02-13 | Common Stock (10386) | Direct | |
| Incentive Stock Option (right-to-buy) | $141.60 | 2027-02-13 | Common Stock (706) | Direct | |
| Non-Qualified Stock Option (right-to-buy) | $178.26 | 2028-02-13 | Common Stock (10148) | Direct | |
| Incentive Stock Option (right-to-buy) | $178.26 | 2028-02-13 | Common Stock (560) | Direct |
Footnotes
F1: The reporting person disclaims beneficial ownership of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein.
F2: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split").
F3: Grant of option to buy 138 shares of Issuer common stock that vests in five annual installments beginning on June 1, 2015, without giving effect to the Stock Split.
F4: Grant of option to buy 3,890 shares of Issuer common stock that vests in one installment on June 1, 2019, without giving effect to the Stock Split.
F5: Grant of option to buy 4,993 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2016, without giving effect to the Stock Split.
F6: Grant of option to buy 628 shares of Issuer common stock that vests in one installment on February 14, 2020, without giving effect to the Stock Split.
F7: Grant of option to buy 11,347 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2017.
F8: Grant of option to buy 1,474 shares of Issuer common stock that vests as to 1 share on February 14, 2017, February 14, 2018 and February 14, 2020, respectively, and as to the remainder on February 14, 2021.
F9: Grant of option to buy 10,386 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2018.
F10: Grant of option to buy 706 shares of Issuer common stock that vests in one installment on February 14, 2022.
F11: Grant of option to buy 10,148 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2019.
F12: Grant of option to buy 560 shares of Issuer common stock that vests in one installment on February 14, 2023.
F13: The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.